Longhu's special resolution has been passed, with 20 billion yuan to be repaid three months in advance.

date
14/08/2025
On August 13, Chongqing Longhu Enterprise Development Co., Ltd.'s proposal to early redeem the "2022 Second Tranche Medium-term Notes" was unanimously approved by the attending holders or their proxies. According to the resolution, Longhu will early redeem "22 Longhu Development MTN002" on August 28, 2025, approximately three months ahead of schedule to repay the principal and interest in one lump sum. "22 Longhu Development MTN002" is the first bond issued under the "Second Arrow" policy framework, which previously set a new low interest rate for privately-owned real estate enterprises' credit enhanced bonds. It was issued with a total amount of 2 billion RMB, a face interest rate of 3%, and a term of 3 years, with an original maturity date of November 30, 2025.
Latest
4 m ago
CITIC Securities stated that the National Medical Security Administration has issued the "Announcement on the Preliminary Review of Drugs and Related Information in the Adjustment of the Drug Catalogs for National Basic Medical Insurance, Maternity Insurance, Work-related Injury Insurance, and the Innovation Drug Catalog for Commercial Insurance by 2025". We believe that the first appearance of the commercial insurance innovation drug catalog is of symbolic significance, which is conducive to the development of commercial insurance and the expansion of the payment end, and more beneficial to the construction of a multi-level medical security system and the innovation of the pharmaceutical industry in China. The introduction process of the basic medical insurance and commercial insurance innovation drug catalogs in this round is relatively fast, and the inclusion of drug varieties exceeds expectations, with a wide range of categories, which highlights the National Medical Security Administration's new definition of "innovation". Continuing our investment strategy viewpoint for the second half of 2025, embracing innovation-driven and internationalization + independent controllable + out-of-hospital marketing mode reform will be a relatively more certain layout direction in the second half of the year. Considering that in addition to overseas gains, the innovative drug sector has received strong domestic policy support, we believe that the era of truly innovative and internationalized pharmaceuticals will bring returns and are expected to drive the sector steadily upwards. We suggest laying out in the second half of the year around the three areas of "innovation-driven and internationalization + independent controllable + out-of-hospital marketing mode reform" in the horizontal dimension, especially in the innovative drug sector with the most beta effect.
See all latestmore